MASLD Mortality Is Cardiovascular, Not Hepatic, Until Late Fibrosis
Fatty liver disease is widely framed as a liver problem, but for most patients the primary mortality driver is cardiovascular — heart attack and stroke — and only late-stage F3-F4 fibrosis crosses over to dominant hepatic mortality. This reframes treatment priorities toward cardiovascular risk reduction, not just hepatic fat reduction.
MASLD (metabolic dysfunction-associated steatotic liver disease) affects roughly 30-40% of adults in developed countries, but the framing of it as primarily a liver problem misleads about where the mortality actually comes from. For the large majority of MASLD patients, who never progress past early fibrosis, the dominant cause of death is cardiovascular disease — heart attack and stroke — not hepatic failure. MASLD travels with the rest of the metabolic syndrome cluster: insulin resistance, atherogenic dyslipidemia, hypertension, and visceral adiposity. The same physiology that deposits fat in hepatocytes also drives atherosclerosis. Multiple cohort studies show that cardiovascular events outnumber liver-related deaths by a wide margin until disease reaches stage F3 or F4 fibrosis, at which point hepatic mortality (cirrhosis decompensation, hepatocellular carcinoma) crosses over to dominate. The practical implication is that effective MASLD treatment for most patients looks like cardiovascular risk reduction: weight loss, blood pressure control, lipid management, glycemic control, and statin therapy. Statins are no longer contraindicated in MASLD — modern guidelines treat MASLD as a statin indication rather than a barrier, and rosuvastatin and atorvastatin have shown hepatic-fat reductions in trials. GLP-1 agonists provide both metabolic and cardiovascular benefit. Hepatology-specific drugs such as resmetirom matter most for the smaller F2-F3 cohort biopsy-confirmed at risk of progression to cirrhosis. A chunk of the patient population also has non-dietary MASLD: post-cholecystectomy bile-flow disruption, ARFID and other eating disorders, persistent insulin resistance after substantial weight loss, and lean MASLD documented at lower BMI in South Asian populations. "Just lose weight" is incomplete advice for these groups.